Page last updated: 2024-10-17

phosphonoacetic acid and Pancreatic Neoplasms

phosphonoacetic acid has been researched along with Pancreatic Neoplasms in 9 studies

Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.

Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Research Excerpts

ExcerptRelevanceReference
"To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma."3.69Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. ( Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H, 1997)
"One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen."1.26Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19903 (33.33)18.7374
1990's5 (55.56)18.2507
2000's1 (11.11)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Whitehead, RP1
Benedetti, JK1
Abbruzzese, JL1
Ardalan, B3
Goodwin, JW1
Balcerzak, SP1
Samlowski, WE1
Lenz, HJ1
Macdonald, JS2
Erlichman, C1
Donehower, RC1
Speyer, JL1
Klecker, R1
Chabner, BA1
Weiss, GR1
Ervin, TJ1
Meshad, MW1
Kufe, DW1
Redei, I1
Green, F1
Hoffman, JP1
Weiner, LM1
Scher, R1
O'Dwyer, PJ2
Ucar, A1
Reddy, R1
Livingstone, AS1
Markoe, A1
Schwade, J1
Richman, SP2
Donofrio, K1
Harstrick, A1
Köhne, CH1
Hiddemann, W1
Preusser, P1
Strumberg, D1
Berns, T1
Seeber, S1
Wilke, H1
Schmoll, HJ1
Rosvold, E1
Schilder, R1
Walczak, J1
DiFino, SM1
Flynn, PJ1
Banerjee, TK1
Heim, WJ1
Engstrom, PF1
Ozols, RF1
Morrell, LM1
Bach, A1
Goodman, P1
Fleming, TR1
Singh, G1
Silberman, H1

Trials

6 trials available for phosphonoacetic acid and Pancreatic Neoplasms

ArticleYear
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Investigational new drugs, 2004, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dose-Res

2004
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
    Investigational new drugs, 1994, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran

1994
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Cancer, 1994, Oct-01, Volume: 74, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modali

1994
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp

1992
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
    Cancer, 1991, Jan-15, Volume: 67, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

1991
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule;

1988

Other Studies

3 other studies available for phosphonoacetic acid and Pancreatic Neoplasms

ArticleYear
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Journal of the National Cancer Institute, 1982, Volume: 68, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule;

1982
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
    Cancer treatment reports, 1982, Volume: 66, Issue:2

    Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th

1982
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:9

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac

1997
chemdatabank.com